Ken Carter
Chairman Black Canyon Bio
Dr Ken Carter is Executive Chairman of Black Canyon Bio and a seasoned biotechnology leader with extensive experience in building and guiding early-stage life sciences companies. He has co-founded and led multiple biotech firms, including NexImmune and Avalon Pharmaceuticals, where he advanced innovative cancer therapies and genomic-based drug discovery platforms. Earlier in his career, he worked in gene mapping at Human Genome Sciences, contributing to the discovery of novel therapeutic targets. In addition to his industry roles, he is involved in academic teaching, including at Johns Hopkins University, where he focuses on biotechnology enterprise development.
Seminars
Wednesday 22nd July 2026
A Comprehensive Approach to Unlocking the Full Potential of Neoantigen Cancer Vaccines
3:30 pm
- Therapeutic cancer vaccines often fail to deliver durable clinical benefit because they stimulate only limited parts of the anti-tumour immune response.
- Effective vaccination requires validated tumour targets, strong immune stimulation, reliable manufacturing, and integration with modern immuno-oncology treatments.
- Black Canyon Bio’s SNAPduo™ platform combines shared tumour antigens, validated personalised neoantigens, and a potent adjuvant to enhance T-cell activation and potentially improve checkpoint inhibitor outcomes in HPV-associated and other solid tumours
